Clinical Trial Update: Efficacy and Safety of Three Times a Day BIAsp-70 Compared to Two Times a Day BIAsp-30 in Subjects With Type 2 Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 study comparing three-times-daily BIAsp-70 to two-times-daily BIAsp-30 in adults with type 2 diabetes to evaluate efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• BIAsp-30 (biphasic insulin aspart protamine 30% / insulin aspart 70%)
• BIAsp-70 (biphasic insulin aspart protamine 70% / insulin aspart 30%)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED